BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250610
DTEND;VALUE=DATE:20250613
DTSTAMP:20260515T035249
CREATED:20250108T111946Z
LAST-MODIFIED:20250108T112021Z
UID:40293-1749513600-1749772799@www.pharmajournalist.com
SUMMARY:7th Annual Allogeneic Cell Therapies Summit
DESCRIPTION:With the autoimmune wave breathing financial life back into the allogeneic space\, and a growing number of oncology pipelines entering the clinic\, the allogeneic community are eagerly anticipating what lies ahead! \nMaking now the ideal time to attend the 7th Annual Allogeneic Cell Therapies Summit (June 10-12 | Boston\, MA)\, your flagship forum uniting the top allogeneic developers including Atara Bio\, Adicet Bio\, Senti Bio\, Glycostem and more. \nWhat Will 2025 Offer? \n\nGround-breaking Clinical Readouts: Dive into the latest results from CAR-T therapies with Atara Bio and Adicet Bio.\nSolid Tumor Breakthroughs: Hear from Senti Bio\, NKILT Therapeutics\, and Synaptimmune on how allogeneic therapies are targeting the tumor microenvironment to unlock entirely new indications.\nManufacturing at Scale: Learn how Tevogen and Cell BioEngines are navigating the complexities of scalable\, high-quality manufacturing to make these therapies commercially viable.\nBeyond Oncology: Broaden your scope by discovering how Biosyngen and Adicet Bio are leveraging allogeneic platforms to address autoimmune disorders.\n\nAs regulatory frameworks evolve to accommodate these revolutionary therapies and investment creeps back into allogeneic development\, staying informed is no longer optional. Get involved today to be part of the conversations solving today’s challenges and shaping tomorrow’s breakthroughs. \nFind out more: https://ter.li/o21go2
URL:http://www.pharmajournalist.com/event/7th-annual-allogeneic-cell-therapies-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250609
DTEND;VALUE=DATE:20250612
DTSTAMP:20260515T035249
CREATED:20250304T113738Z
LAST-MODIFIED:20250304T113738Z
UID:40624-1749427200-1749686399@www.pharmajournalist.com
SUMMARY:Innovation in Psychosis Therapeutics Summit
DESCRIPTION:The Innovation in Psychosis Therapeutics Summit is the premier industry forum dedicated to advancing next-generation approaches for psychosis treatment. As 2025 marks a pivotal year for psychosis drug development—with a surge in clinical advancements and key collaborations gaining momentum—this inaugural event unites the brightest minds in biotech and pharma to overcome critical challenges in drug discovery and development. \n \nDesigned specifically for R&D leaders\, this summit is uniquely positioned to tackle the biggest hurdles in the field\, including translational validity\, patient heterogeneity\, placebo effect\, and trial scalability. By bringing together 60+ key stakeholders from discovery\, preclinical\, translational\, and clinical development\, this meeting provides a platform to collaborate\, exchange insights\, and shape the future of psychosis treatment. \nWith the growing urgency to address the significant unmet need in psychosis and the limitations of current atypical antipsychotics\, the time is now to drive innovation forward. Join the conversation as industry pioneers build on Cobenfy’s breakthrough success and explore cutting-edge strategies to develop more effective\, better-tolerated therapeutics across the psychosis spectrum. \nDon’t miss this brand-new opportunity to connect with thought leaders\, gain critical insights\, and be at the forefront of transforming psychosis R&D. \nTo know more visit: https://ter.li/9yj2vx
URL:http://www.pharmajournalist.com/event/innovation-in-psychosis-therapeutics-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250603
DTEND;VALUE=DATE:20250606
DTSTAMP:20260515T035249
CREATED:20250228T121911Z
LAST-MODIFIED:20250228T121911Z
UID:40598-1748908800-1749167999@www.pharmajournalist.com
SUMMARY:2nd Structure-Based Drug Design Summit
DESCRIPTION:With tightening budgets and increasing pressure to de-risk R&D\, pharma and biotech are shifting their focus toward smarter\, more efficient drug design. Companies are investing more in enabling technologies—from computational modeling and AI-driven predictions to structural biology techniques like Cryo-EM\, NMR\, and X-ray crystallography—to improve rational drug design and enhance decision-making early in discovery. \nWhile AI-powered structure prediction is transforming the landscape—recognized by the 2024 Nobel Prize for Google DeepMind’s AlphaFold2— its true impact depends on experimental validation. The ability to integrate computational insights with high-resolution structural data is now essential for unlocking complex targets and accelerating drug discovery. \nCryo-EM continues to push the limits of resolution for complex targets and Cryo-ET is emerging as a potential game-changer for biopharma – the future of structure-based drug design is here. \nThe 2nd Structure-Based Drug Design Summit is the only industry-dedicated meeting bringing together the latest advancements in integrative structural biology and computational tools to accelerate early drug discovery. Across three days of expert-led discussions and case studies\, you’ll gain insights into how leading scientists are leveraging Cryo-EM\, NMR\, X-ray crystallography\, and AI to solve high-value targets and drive rational drug design across small molecules\, peptides\, biologics\, and vaccines. \nWith coverage of design of TPDs\, molecular glues\, vaccines\, antibodies\, and mRNA\, GPCRs and membrane protein targeting therapeutics plus much more! \nThe field is evolving—don’t get left behind. Expand your network and join 80+ structural biologists\, medicinal chemists\, protein engineers\, and computational chemists in Boston this June and be part of the next wave of structure-based drug design innovation.
URL:http://www.pharmajournalist.com/event/2nd-structure-based-drug-design-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250528
DTEND;VALUE=DATE:20250530
DTSTAMP:20260515T035249
CREATED:20250219T115152Z
LAST-MODIFIED:20250219T115152Z
UID:40525-1748390400-1748563199@www.pharmajournalist.com
SUMMARY:3rd Gene Therapy Potency Assay Summit
DESCRIPTION:Accelerating the Route to Commercialization with Robust Potency Assay Development \nFollowing a challenging year in the gene therapy field\, the 3rd Gene Therapy Potency Assay Summit returns at a crucial time when drug developers increasingly recognize that a robust potency assay is fundamental to both clinical success and commercial viability. As regulatory expectations continue to evolve\, it has never been more important to develop assays that are accurate\, reproducible\, and aligned with regulatory standards. \nWhile many industry meetings touch on potency in a broad or non-technical manner\, this summit stands apart as the only event fully dedicated to the complexities of potency assay development. With an emphasis on deep technical discussions\, attendees will gain unparalleled insights into phase-appropriate assay development\, methodology advancements\, reducing lot-to-lot variability\, and meeting evolving regulatory expectations. By bringing together a specialized community of Analytical Development\, Quality Control\, and Regulatory experts\, this meeting offers a unique platform to discuss challenges\, share strategies\, and explore innovative solutions. \nOne of the key highlights of this year’s agenda is the session “Navigating Regulatory Requirements for Gene Therapy Potency Assays”\, presented by Melody Dai\, Vice President\, Head of Regulatory Affairs & CMC at Novasenta. This session\, taking place at 9:00 AM on Day 1\, will provide an in-depth exploration of regulatory strategies for potency assays\, covering both early and ongoing regulatory engagement. Attendees will learn how to build effective relationships with regulatory agencies\, navigate evolving requirements\, and prepare for critical regulatory meetings and submissions. By leveraging insights from experts with hands-on experience in clinical-stage gene therapy products\, this session will offer practical guidance that extends beyond theoretical discussions. \nWith a carefully curated agenda and contributions from industry leaders\, the 3rd Gene Therapy Potency Assay Summit provides an essential opportunity to advance potency assay strategies\, enhance regulatory preparedness\, and accelerate the path to commercialization. Whether you are refining your assay methodologies\, tackling regulatory complexities\, or preparing for the next phase of development\, this event will equip you with the expertise and connections needed to drive success in gene therapy. \nFind Out More Now!
URL:http://www.pharmajournalist.com/event/3rd-gene-therapy-potency-assay-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250528
DTEND;VALUE=DATE:20250530
DTSTAMP:20260515T035249
CREATED:20250217T143826Z
LAST-MODIFIED:20250217T143826Z
UID:40519-1748390400-1748563199@www.pharmajournalist.com
SUMMARY:4th Circular & Self-Amplifying RNA Therapeutics Summit
DESCRIPTION:Join the 4th Circular & Self-Amplifying RNA Therapeutics Summit! \nUnleashing the Next Generation of RNAs for Widespread Therapeutic Applications \nWith CSL Seqirus and Arcturus Therapeutics successfully developing the first approved self-amplifying RNA vaccine\, the field of next generation RNAs celebrates the potential of circular and self-amplifying RNAs to provide improved stability\, durability\, longevity and efficacy for treating a wide array of diseases. \nThis May\, the 4th Circular & Self-Amplifying RNA Therapeutics Summit (previously known as ‘Next Generation RNA Therapeutics Summit) is landing back in Boston\, as the unique opportunity to unite with leading stakeholders in the next generation RNA field\, including the likes of Sail Biomedicines\, Merck\, Novo Nordisk\, Replicate Bioscience and more. This is your one-stop shop to hear the latest approaches and applications of circular and self-amplifying RNA therapeutics and vaccines and gain actionable insights for fast-tracking your RNA programs toward the clinic. \nJoin 80+ RNA experts navigating through challenges such as RNA design\, delivery\, purity\, and manufacturing to accelerate high-quality and scalable next-generation RNA therapeutics and vaccines towards approval and the patients in need. \nTo know more visit: https://ter.li/lemzh2
URL:http://www.pharmajournalist.com/event/4th-circular-self-amplifying-rna-therapeutics-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250527
DTEND;VALUE=DATE:20250530
DTSTAMP:20260515T035249
CREATED:20250416T103747Z
LAST-MODIFIED:20250416T103747Z
UID:40951-1748304000-1748563199@www.pharmajournalist.com
SUMMARY:2nd Cell & Gene Therapy Pricing & Reimbursement Summit
DESCRIPTION:Current limitations across pricing\, coverage\, and payment frameworks are lasering out and hindering global access to many approved cell and gene therapies (CGTs). The Cell & Gene Therapy Pricing & Reimbursement Summit is here to change that. \nReturning for its 2nd edition\, this unique summit will share real-world case studies of success and setback in ensuring patients can access CGTs to spearhead reform in this thorny landscape. \nIndustry-led discussions will center on innovative payment models being developed and applied\, new stop-loss and reinsurance programs\, and how leading companies are ensuring coverage and uptake of their commercialized therapies. You’ll also leave with actionable learnings from recent CMS policy changes\, including the Access Model\, Medicaid Drug Rebate Program Final Rule\, and proposed increases to inpatient CAR-T reimbursement rates. \nJoin leading biopharma\, government agencies\, commercial payers\, academics\, and market access-specialist service providers – to align on the current market access strategy and policy challenges hindering widespread adoption of these ground-breaking therapies\, enhance your payer coverage and improve patient access. \nTo know more visit: https://ter.li/0g5eq9
URL:http://www.pharmajournalist.com/event/2nd-cell-gene-therapy-pricing-reimbursement-summit/
LOCATION:Marriott Washington Capitol Hill\, 175 L Street NE\, WA\, 20002\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250527
DTEND;VALUE=DATE:20250530
DTSTAMP:20260515T035249
CREATED:20250307T113641Z
LAST-MODIFIED:20250307T113641Z
UID:40683-1748304000-1748563199@www.pharmajournalist.com
SUMMARY:3rd Retinal Imaging Biomarkers & Endpoints Summit
DESCRIPTION:The 3rd Retinal Imaging Biomarkers & Endpoints Summit will bring together leading experts spanning medical directors\, researchers\, clinical\, and imaging scientists from more than 30 organizations spearheading ophthalmic development with deep learning systems and sophisticated AI imaging technologies. It’s here they will explore the latest advancements in retinal imaging\, biomarkers\, and endpoints for ophthalmic drug development. \nThis highly anticipated meeting will delve into the evolving landscape of retinal diseases\, offering in-depth discussions on innovative imaging techniques\, biomarker discovery\, and the critical role of endpoints in clinical trials. Attendees will have the opportunity to engage with top-tier scientists\, researchers\, and industry leaders who will be presenting cutting-edge research\, techniques\, and case studies\, providing you with hyper-relevant insights to accelerate your ophthalmic development. \nTopics will cover a range of retinal conditions\, including dry and wet AMD\, GA\, GR\, and DME\, focusing on the identification and validation of biomarkers that are vital for diagnosis\, prognosis\, and treatment response assessment. This meeting is the perfect bridge for those developing and using novel technologies to ensure the efficacious development of endpoints for regulatory approval. \nAttendees will benefit from interactive workshops\, panel discussions\, and case studies\, providing practical insights into the real-world challenges and opportunities in retinal disease research. Plus\, with 8+ hours of dedicated networking sessions designed to ensure attendees get to meet everyone in the room\, it’s a fantastic opportunity to build valuable connections and strengthen collaboration which will aid in fostering partnerships that will drive the future of retinal imaging and treatment outcomes. \nAnd with sessions being delivered by Alexion\, Opus Genetics\, Inflammx\, Bausch + Lomb\, REGENXBIO\, and many more you won’t want to miss this! \nWhether you’re a researcher\, drug developer\, clinician or solution provider\, the 3rd Retinal Imaging Biomarkers & Endpoints Summit promises to be a pivotal point in the calendar for those involved in the development of therapies for retinal diseases. \nJoin us to be at the forefront of this rapidly advancing field and contribute to the next wave of innovations in retinal health… \nView the event guide for more information: https://ter.li/hcmzr0 \nSecure your pass: https://ter.li/tq8jmz
URL:http://www.pharmajournalist.com/event/3rd-retinal-imaging-biomarkers-endpoints-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250520
DTEND;VALUE=DATE:20250523
DTSTAMP:20260515T035249
CREATED:20250422T121846Z
LAST-MODIFIED:20250422T122446Z
UID:40956-1747699200-1747958399@www.pharmajournalist.com
SUMMARY:6th Gene Therapy Analytical Development Summit Europe
DESCRIPTION:The 6th Gene Therapy Analytical Development Summit Europe is the leading platform for advancing gene therapy analytics\, from IND/IMPD filings to clinical trials and regulatory approvals. As the field moves toward late-stage development\, gain industry-focused insights tailored for Europe. \nJoin 24+ experts to tackle characterisation\, stability\, contamination risks\, and comparability across vectors and diseases. Network with biotech\, pharma\, MHRA\, and British Pharmacopoeia to share solutions and shape the future of gene therapy. \nDon’t miss the chance to explore analytical precision\, QC strategy\, and the delivery of safe\, effective therapies! \nTo know more visit: https://ter.li/w8deua
URL:http://www.pharmajournalist.com/event/6th-gene-therapy-analytical-development-summit-europe/
LOCATION:Novotel London West\, 1 Shortlands\, Hammersmith\, London\, W6 8DR\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250520
DTEND;VALUE=DATE:20250523
DTSTAMP:20260515T035249
CREATED:20250225T113954Z
LAST-MODIFIED:20250225T113954Z
UID:40583-1747699200-1747958399@www.pharmajournalist.com
SUMMARY:4th GPCRs-Targeted Drug Discovery Summit
DESCRIPTION:The 4th GPCR-Targeted Drug Discovery Summit: Transforming the Discovery of Novel GPCR-Targeted Therapies. \nWith positive clinical read outs by Tectonic Therapeutics and recent funding rounds for Confo Therapeutics & Septerna\, the potential for novel GPCR drug classes to treat a plethora of diseases grows. Now more than ever\, there is a need for the community to come together to share scientific advancements and collaboration opportunities across the full spectrum of GPCR drugs\, from small molecules to therapeutic proteins and antibodies. \nThe 4th GPCRs-Targeted Drug Discovery Summit is returning to Boston to showcase the hottest targets of interest\, mechanism of action of new GPCR ligands\, cutting-edge computational tools to identify high-potential candidates\, and effective translational strategies to drive forward discovery & development pipelines to patients in need.\n\nFind out everything you need to know about the Summit here: https://ter.li/2c54a7
URL:http://www.pharmajournalist.com/event/4th-gpcrs-targeted-drug-discovery-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250519
DTEND;VALUE=DATE:20250521
DTSTAMP:20260515T035249
CREATED:20250402T111945Z
LAST-MODIFIED:20250402T111945Z
UID:40815-1747612800-1747785599@www.pharmajournalist.com
SUMMARY:TPD & Induced Proximity Pharma Partnering Summit
DESCRIPTION:From molecular glue discovery to the development of degrader-antibody conjugates\, pharma is transforming through strategic transactions and by leveraging protein degradation technologies to expand target discovery and drug previously ‘undruggable’ targets. \nThis provides biotech with the opportunity to understand pharma’s targets of interest and the options for increased specificity and selectivity compared to traditional molecules. \nJoin the TPD & Induced Proximity Pharma Partnering Summit to accelerate partnership interest in your protein degradation pipeline or platform\, by hearing first-hand: \n\nWhat: What are pharma’s targets of interest\, and what data is sparking or prohibiting deal-making across TPD?\nWho: Who is the right person at each pharma\, specifically for induced proximity assets?\nHow: How are pharma analyzing data for a research collaboration versus a licensing deal?\n\nVIEW THE FULL EVENT GUIDE \nSecure your place here or get in touch with the team – info@hansonwade.com
URL:http://www.pharmajournalist.com/event/tpd-induced-proximity-pharma-partnering-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:General Enquiries: info@hansonwade.com or Partnership Enquiries: sponsor@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250513
DTEND;VALUE=DATE:20250516
DTSTAMP:20260515T035249
CREATED:20250214T120932Z
LAST-MODIFIED:20250214T120932Z
UID:40492-1747094400-1747353599@www.pharmajournalist.com
SUMMARY:3rd Precision Medicine in Inflammatory Bowel Disease Summit
DESCRIPTION:Following a year of exceptional progress in IBD drug development\, fierce competition in clinical trials for Chron’s Disease and Ulcerative Colitis remains high\, and it’s time for biopharma to push the boundaries of efficacy and distinguish their therapies amongst the market. \nFeaturing three days of data-driven sessions from 25+ world-class speakers\, the 3rd Precision Medicine in Inflammatory Bowel Disease returns as the field’s most comprehensive learning and networking forum; dedicated to showcasing the latest data and advances in IBD therapeutic development. \nSee the full program here: https://ter.li/tjjok6 \nWith transformative advancements in disease understanding\, AI-powered biomarker development\, patient stratification\, and advanced monitoring techniques paving the way for a new era of precision IBD therapies\, join 80+ IBD specialists to: \n\nRefine models and proof-of-concept studies to reduce clinical trial failure rates and improve translational outcomes\nInnovate treatment pathways to optimize safety and efficacy\nMinimize adverse events while enhancing therapeutic synergies\nLeverage emerging therapeutic modalities to refine patient selection and optimize therapeutic outcomes\n\nWhen & Where: May 13-15\, 2025 | Boston\, MA \nWho: 80+ Precision Medicine\, Diagnostics\, Translational\, Clinical\, Computational Biology\, Gastrointestinal and Inflammation experts \nAgenda: https://ter.li/tjjok6
URL:http://www.pharmajournalist.com/event/3rd-precision-medicine-in-inflammatory-bowel-disease-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250512
DTEND;VALUE=DATE:20250515
DTSTAMP:20260515T035249
CREATED:20250225T112204Z
LAST-MODIFIED:20250225T112204Z
UID:40566-1747008000-1747267199@www.pharmajournalist.com
SUMMARY:4th ALS Drug Development Summit
DESCRIPTION:The ALS Drug Development Summit is the definitive industry-led forum dedicated to advancing breakthroughs in ALS therapeutics. With the field evolving rapidly\, recent milestones—such as Insitro’s AI-driven target discovery with Bristol Myers Squibb and Dewpoint Therapeutics’ collaboration with Mitsubishi Tanabe Pharma America on TDP-43 condensate modulators—highlight the momentum in novel drug discovery. Meanwhile\, QurAlis’ clinical trials for QRL-101 and QRL-201 and innovations in biomarker platforms are reshaping the treatment landscape. \nJoin 200+ scientific leaders in Boston to tackle key challenges in target validation\, biomarker development\, and clinical trial optimization—driving progress toward effective ALS and FTD therapies. \nTo know more visit: https://ter.li/48rlwg
URL:http://www.pharmajournalist.com/event/4th-als-drug-development-summit/
LOCATION:Revere\, 200 Stuart St\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250506
DTEND;VALUE=DATE:20250509
DTSTAMP:20260515T035249
CREATED:20250220T124530Z
LAST-MODIFIED:20250220T124530Z
UID:40548-1746489600-1746748799@www.pharmajournalist.com
SUMMARY:2nd ADC Payload Summit
DESCRIPTION:The 2nd ADC Payload Summit (May 6-8 | Boston\, MA) is the first and only conference exclusively focusing on ADC payloads\, helping you to reimagine the medicinal chemistry of traditional cytotoxic payloads while scouting the next generation of ADC payload innovations. \n \nWith novel payload categories such as degraders\, RNA polymerase II inhibitors\, immunomodulators\, gene silences\, and splice modulators entering the clinic\, don’t miss this opportunity to meet with fellow peers to explore the benefits of these diverse mechanisms of action to develop the next blockbuster ADC. \nThis event will also feature cutting-edge data presentations from emerging players in the field\, including Lycia Therapeutics and Heidelberg Pharma\, showcasing their latest advancements in payload technologies and clinical trial outcomes. With 80+ professionals from across the ADC landscape in attendance\, the summit offers ample networking opportunities to foster collaboration\, exchange ideas\, and drive the future of ADC therapy forward. \nOver three days of deep discussions and collaborative sessions\, attendees will gain practical insights into optimizing payload efficacy\, improving structure-activity relationships\, and exploring the latest payload classes entering the clinic. \nHere are some of the agenda highlights you cannot afford to miss: \n– Gain insights from Eisai on “Engineering STING/TLR Agonist Payloads to Amplify Anti-Tumor Immune Responses Without Triggering Cytokine Induction” exploring the therapeutic niche and potential of STING agonist payloads. \n– Join Takeda in “Navigating the Evolution of ADC Payloads – From Topo1 Success to Future Innovation” to discuss why Topo1 inhibitors dominated the clinic so fast\, what other modes of action and payload classes need to do to match that clinical success\, and where there is whitespace for novel payloads to gain ground in a competitive ADC landscape. \n– Hear from Merck on “Accelerating Degrader-Antibody Conjugate Design Through Strategic Integration of Traditional ADC & Expertise in TPD” to learn about translating physicochemical property optimization strategies from traditional ADCs to address unique degrader payload solubility and stability challenges. \nDon’t miss this opportunity to connect with the ADC community and shape the future of payload design. Join us in Boston for this exclusive event and be at the forefront of ADC innovation. \nTo know more visit: https://ter.li/j0dvm6
URL:http://www.pharmajournalist.com/event/2nd-adc-payload-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250506
DTEND;VALUE=DATE:20250509
DTSTAMP:20260515T035249
CREATED:20250116T114600Z
LAST-MODIFIED:20250116T114600Z
UID:40301-1746489600-1746748799@www.pharmajournalist.com
SUMMARY:3rd mRNA Process Development & Manufacturing Summit Europe
DESCRIPTION:The 3rd mRNA Process Development & Manufacturing Summit 2025 returns as Europe’s premier industry-focused forum\, dedicated to optimizing process development for mRNA therapeutics and vaccines. This event will address end-to-end process optimisation\, regulatory compliance to streamline approvals\, while also advancing scalable and cost-efficient manufacturing solutions\, to support drug developers in delivering safer and more effective mRNA drugs to patients faster. \nBringing together leading experts from CEPI\, Merck\, CureVac\, BioNTech\, Altamira\, Genevation\, and more\, this summit will showcase cutting-edge advancements in end-to-end process development and manufacturing to support the production of high-quality\, cost-effective mRNA therapeutics at scale. \nDownload the event guide for full details: https://ter.li/4omn9n
URL:http://www.pharmajournalist.com/event/3rd-mrna-process-development-manufacturing-summit-europe/
LOCATION:Hotel Palace Berlin\, Germany
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250429
DTEND;VALUE=DATE:20250502
DTSTAMP:20260515T035249
CREATED:20250317T140929Z
LAST-MODIFIED:20250317T140929Z
UID:40719-1745884800-1746143999@www.pharmajournalist.com
SUMMARY:2nd GLP-1-Based Therapeutics Summit
DESCRIPTION:The 2nd GLP-1-Based Therapeutics Summit is an exclusive gateway to competitive intelligence into the continued potential of cutting-edge GLP-1s for obesity\, weight loss\, diabetes\, and beyond. Join us to hear the latest clinical data on combination therapies to enhance muscle preservation\, indication expansion into new areas\, and strategies to improve the efficacy\, tolerability\, and durability of GLP-1s. With these drugs continuing to dominate the headlines\, there is no better time to unite with 100+ C-level executives\, decision-makers\, and scientists at the forefront of the rapidly evolving world of GLP-1-Based therapeutics. \nLearn more: https://ter.li/b0yt9f
URL:http://www.pharmajournalist.com/event/2nd-glp-1-based-therapeutics-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250429
DTEND;VALUE=DATE:20250502
DTSTAMP:20260515T035249
CREATED:20250204T091737Z
LAST-MODIFIED:20250204T091823Z
UID:40418-1745884800-1746143999@www.pharmajournalist.com
SUMMARY:2nd Measuring Patient Engagement Summit
DESCRIPTION:As the healthcare industry evolves\, patient engagement has become a crucial factor in shaping clinical trials\, accelerating regulatory approvals\, and improving the overall patient experience. \nYet\, amidst a challenging funding environment\, empowered patients rightfully demanding greater involvement in treatment decisions\, and regulatory bodies requiring transparent reporting of patient engagement activities\, it has become more critical than ever to establish quantitative measures for assessing the impact of these initiatives. \nThe 2nd Annual Measuring Patient Engagement Summit 2025 is the premier event dedicated to addressing this challenge. Bringing together top experts from Patient Engagement\, Advocacy\, Affairs\, Experience\, Insights\, and Marketing\, this summit offers a platform for thought leaders to share data-driven strategies and actionable insights. Attendees will explore innovative case studies that showcase how patient engagement initiatives can be effectively measured\, ensuring they deliver real impact while meeting compliance and ROI expectations. \nKey topics will include: \n\nEstablishing standardized metrics for patient engagement success\nAligning patient engagement strategies with regulatory expectations\nDemonstrating ROI to internal and external stakeholders\nLeveraging patient insights to improve trial design and healthcare outcomes\n\nBy uniting industry leaders to develop a consistent framework for measuring patient engagement\, this event ensures that patient-centered innovation remains at the forefront of healthcare transformation. \nJoin us to drive measurable\, meaningful progress in patient engagement — because when we quantify what matters\, we create a healthcare system that works for everyone. \nTo know more visit: www.measuring-patient-engagement-summit.com
URL:http://www.pharmajournalist.com/event/2nd-measuring-patient-engagement-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250428
DTEND;VALUE=DATE:20250501
DTSTAMP:20260515T035249
CREATED:20250116T115710Z
LAST-MODIFIED:20250116T115805Z
UID:40311-1745798400-1746057599@www.pharmajournalist.com
SUMMARY:4th ADC Analytical Development Summit
DESCRIPTION:Unlock the Future of ADC Analytics at the 4th ADC Analytical Development Summit! \nWhen: April 2025\nWhere: Boston \nThe 4th ADC Analytical Development Summit is back\, bringing together top minds and innovators to tackle the unique analytical challenges of antibody-drug conjugates. With ADCs becoming more complex and regulatory requirements tightening\, this event will be your ultimate guide to mastering strategies that ensure high-quality products and seamless regulatory submissions. \nView the program here: https://ter.li/hi4hm1 \n\nWhy You Can’t Miss This Summit: \n3 Days of Cutting-Edge Scientific Content \nExplore sessions that cover critical topics\, including: \n\nOptimizing DAR quantification\nImproving aggregation analysis\nRefining impurity profiling for advanced ADC development\n\n25+ Expert Speakers \nLearn from top industry leaders and innovators\, featuring experts from: \n\nAstraZeneca\nAbbVie\nSutro Biopharma\nMerck\n…and many more!\n\n6+ Hours of Interactive Workshops \nParticipate in hands-on workshops to dive deeper into: \n\nStrategies for accelerated approvals\nAdvanced profiling techniques for product characterization\nPotency optimization for improved therapeutic outcomes\nCrafting data packages for smooth regulatory submissions\n\n5+ Hours of High-Impact Networking \nConnect with over 120 analytical scientists and quality control specialists to build valuable collaborations and share expertise. \nFind out more here: https://ter.li/hi4hm1
URL:http://www.pharmajournalist.com/event/4th-adc-analytical-development-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250422
DTEND;VALUE=DATE:20250425
DTSTAMP:20260515T035249
CREATED:20241128T082522Z
LAST-MODIFIED:20241128T082522Z
UID:40196-1745280000-1745539199@www.pharmajournalist.com
SUMMARY:LEAP HR: Life Sciences West
DESCRIPTION:LEAP HR: Life Sciences West is your chance to explore how leading and emerging biopharma organizations are navigating industry volatility and preparing for the workforce of tomorrow. As the sector recovers from funding challenges and workforce reductions\, discover innovative ways to align your HR strategy with evolving business needs in 2025 and beyond. \nJoin 200+ HR leaders to uncover how the most agile organizations are reshaping total rewards strategies to gain a competitive edge in a fiercely competitive talent market. Learn how they’re redefining employee engagement to boost retention and creating flexible workforce planning strategies to adapt to rapid industry changes. \nThis is your opportunity to rethink HR practices and position your organization for long-term success in Life Sciences. \nTo know more visit: https://ter.li/fxwk88
URL:http://www.pharmajournalist.com/event/leap-hr-life-sciences-west/
LOCATION:Grand Hyatt San Francisco\, 345 Stockton St\, San Francisco\, CA\, 94108\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:leaphr@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250409
DTEND;VALUE=DATE:20250411
DTSTAMP:20260515T035249
CREATED:20250228T122457Z
LAST-MODIFIED:20250228T122457Z
UID:40603-1744156800-1744329599@www.pharmajournalist.com
SUMMARY:Tumour Models Summit Nordics
DESCRIPTION:Welcome to the first ever Tumour Models Summit Nordics. This April\, the critically acclaimed Tumour Models series will be coming to the Nordics for the first time ever\, uniting more than seventy pharma\, biotech\, and research leaders across the Nordic biotech landscape. \nThe inherent heterogeneity of cancer – both inter-patient and intra-tumoral – remains a significant challenge in cancer modelling. With only 5% of cancer drugs successfully advancing to clinical trials\, there is a critical need for more accurate and predictive models to guide therapeutic development. \nTo serve this need\, the Tumour Models Summit Nordics will unite pharma\, biotech\, and research leaders from across the thriving Nordic biotech ecosystem to tackle this challenge head-on for the first time ever. Experts working across preclinical\, translational\, discovery\, toxicity\, and biology will gather in Stockholm this April to collaborate and overcome the industry’s biggest obstacles for 2025. As the region’s only industry-led event of its kind\, this summit provides a rare opportunity to connect with top experts from these developmental areas. \nGain insights into the cutting-edge innovation in in vivo and in vitro tumour modelling\, discover strategies to de-risk your studies\, and learn how to refine your drug development pipeline. \nKey highlights of the agenda include: \n\nLeveraging cutting-edge 3D in vitro models with Roche\nTarget/receptor axis modelling with Anocca\nHumanised mouse models with BioInvent\nAdvanced omics data with Curacell\nTreating solid tumours with Hemispherian\n\nPrevious attendees of the Tumour Models Summits in Boston\, San Francisco\, and London have celebrated the summit’s range\, relevance\, and focus with comments such as\, “This summit included the most cutting-edge achievements and potential collaborations in the scientific and industrial world” (Roche)\, and “The conference exceeded my expectations. The talks were very relevant to my day-to-day work as in vivo scientist in a cell therapy company. I enjoyed the networking; attendees were very approachable” (Arsenal Biosciences). \nFind out why they said this and secure your free pass to join us to engage with decision-makers\, explore groundbreaking solutions\, and accelerate the path from lab to patient in today’s rapidly evolving landscape. \nWe’ll see you there! \nGet your free pass now whilst still available: https://ter.li/qdc9zo
URL:http://www.pharmajournalist.com/event/tumour-models-summit-nordics/
LOCATION:Hilton Stockholm Slussen\, Guldgränd 8\, Stockholm\, 104 65\, Sweden
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250408
DTEND;VALUE=DATE:20250411
DTSTAMP:20260515T035249
CREATED:20250214T121248Z
LAST-MODIFIED:20250214T121248Z
UID:40497-1744070400-1744329599@www.pharmajournalist.com
SUMMARY:15th World Clinical Biomarkers & Companion Diagnostics Summit Europe
DESCRIPTION:As recent advances in small molecules\, ADCs\, cell\, and gene therapies poise novel precision therapies from the bench to the clinic\, the 15th World Clinical Biomarkers & Companion Diagnostics Summit Europe returns as the industry-leading end-to-end forum for Europe’s precision medicine community. \nOver three days\, 170+ key stakeholders from across Europe working in Biomarkers\, Translational Medicine\, Precision Medicine\, and Companion Diagnostics will come together to: \n\nBolster biomarker discovery and validation\nImplement novel technologies and trials\nPioneer digital and AI-enabled innovations\nOptimise drug-diagnostic co-development\nStreamline CDx development and commercialisation\nNavigate IVDR-adherence\n\nWhen? 8th-10th April\, 2025 \nWhere? London\, UK \nSee the brochure: https://ter.li/exx85v \nWith free* tickets available for biopharma\, check our T&Cs\, or view our early bird savings and group discounts: https://ter.li/5uhfl8
URL:http://www.pharmajournalist.com/event/15th-world-clinical-biomarkers-companion-diagnostics-summit-europe/
LOCATION:London\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250401
DTEND;VALUE=DATE:20250404
DTSTAMP:20260515T035249
CREATED:20250127T201431Z
LAST-MODIFIED:20250127T201431Z
UID:40370-1743465600-1743724799@www.pharmajournalist.com
SUMMARY:6th TCR-Based Therapies Summit
DESCRIPTION:Returning as the only event created selectively for and by the TCR community\, the 6th TCR-based Therapies Summit (April 1-3\, 2025 | Boston\, MA) is your unique opportunity to connect and collaborate with TCR developers and experts to battle the specific discovery\, preclinical and clinical challenges created by T cell receptor biology to advance cell- and bispecific approaches. \nView the 25+ experts speaking in 2025 including Adaptimmune\, Immunocore\, Immatics\, BioNTech\, T-Knife\, TScan\, and Affini-T Therapeutics. \nView the full lineup of presenting companies in the 2025 Event Guide. \nReturning as a much-loved forum by industry leaders in this close-knit community\, I’m sure you want to know what’s new for the 2025 meeting: \n\nPlethora of new data: Over 60% of talks will share new data\, including clinical insights and advances\, novel target case studies\, and innovations utilizing AI\, machine learning\, engineering methods\, and cell tracking\nBreadth of TCR Approaches: Uncover the realm of TCR targeting methods including TCR-Ts\, TCR-NKs\, bispecifics\, T-cell engagers\, TCR-like antibodies\, and mimics\, and distinguishing the optimal approach for different indications\n7 New Companies & 85% New Speakers: Unlock innovations from companies such as Moonlight Bio\, Synteny\, Alkemist Bio\, Pan Cancer T\, and Aethon Therapeutics making their TCR-Based Therapies Summit debut and hear new perspectives from a highly refreshed speaker faculty\nApplications Beyond Oncology: Discover how TCR therapies can be utilized to treat novel indications\, such as autoimmunity and infectious diseases\, and harness cross-learnings to propel your therapeutic development\n\nView the full program. \nFollowing Adaptimmune’s milestone approval\, the 2025 meeting is anticipated to be one of the best yet. With so much to celebrate\, momentum to capture\, novel insights\, and collaboration with like-minded experts at the only TCR-specific event. \nQuick links: Website | Event Guide | Register
URL:http://www.pharmajournalist.com/event/6th-tcr-based-therapies-summit/
LOCATION:The Revere Hotel Boston Common\, 200 Stuart St\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250401
DTEND;VALUE=DATE:20250404
DTSTAMP:20260515T035249
CREATED:20241204T190232Z
LAST-MODIFIED:20241204T190232Z
UID:40220-1743465600-1743724799@www.pharmajournalist.com
SUMMARY:2nd Peptide-Based Therapeutics Summit
DESCRIPTION:The 2nd Peptide-Based Therapeutics Summit will return to Boston in April 2025\, bringing together over 80 experts in peptide computational science\, medicinal chemistry\, and formulation to discuss the latest advancements shaping the next generation of peptide-based therapies—from early-stage discovery to clinical application. \nDownload the three-day program here: https://ter.li/rrvg1v \nThis year’s summit will highlight groundbreaking innovations in peptide therapeutics\, including: \n\nPeptide 3D structure prediction\, hit generation\, and lead optimization\, featuring insights from Chugai Pharmaceutical\, PeptiDream\, and Insamo\nStrategies for optimizing oral bioavailability and cell permeability in peptide design\, with contributions from Orbis Medicines and Ohio State University\nPeptide formulation techniques for optimal target binding\, solubility\, stability\, and safety\, with expertise from Halozyme and Oramed Pharmaceuticals\n\nJoin us to shape your peptide drug discovery and development strategy for 2025 and discover the therapeutic potential of cutting-edge peptide-based medicines.
URL:http://www.pharmajournalist.com/event/2nd-peptide-based-therapeutics-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250401
DTEND;VALUE=DATE:20250404
DTSTAMP:20260515T035249
CREATED:20241127T123831Z
LAST-MODIFIED:20241127T123902Z
UID:40151-1743465600-1743724799@www.pharmajournalist.com
SUMMARY:Nasal Formulation & Delivery Summit
DESCRIPTION:With nasal delivery systems offering faster absorption and non-invasive administration\, they are becoming a cornerstone of modern therapeutics. Whether for nose-to-brain delivery or emergency use\, nasal delivery is opening a new era of more efficient drug and vaccine administration with life-saving potential. However\, challenges in biologics formulation\, along with renewed interest from major pharmaceutical companies and investors\, raise questions about how other companies are addressing development obstacles and the most effective strategies to secure funding. \nDedicated to navigating investment pathways for nasal companies\, boosting drug bioavailability in target regions\, optimizing translational modelling\, and determining the efficacy of delivery devices\, the 3rd Nasal Formulation & Delivery Summit will unite biotechs and innovative start-ups to share case studies and best practices in optimizing nasal drug delivery across different therapeutic areas. \nDownload the event guide for full details: https://ter.li/qd1z5z \nEarly bird savings and group discounts up to 20% are available\, check out the options here: https://ter.li/u7ehtp
URL:http://www.pharmajournalist.com/event/nasal-formulation-delivery-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250326
DTEND;VALUE=DATE:20250328
DTSTAMP:20260515T035249
CREATED:20250206T124811Z
LAST-MODIFIED:20250206T124811Z
UID:40435-1742947200-1743119999@www.pharmajournalist.com
SUMMARY:2nd DNA Process Development & Manufacturing Summit
DESCRIPTION:The 2nd DNA Process Development & Manufacturing Summit: Accelerating Innovative Advanced Therapies with Revolutionary Plasmid & Enzymatic DNA. \nWith the plasmid DNA manufacturing market set to rise to $39.3Bn by 2033\, and the demand for advanced therapies continuing to surge as gene therapy reaches new heights and DNA vaccines promise to transform outbreak response\, there has never been a more crucial time to revolutionize the production of high-quality DNA as a starting material and API. \nThe 2nd DNA Process Development & Manufacturing Summit 2025 returns as the world’s only industry-dedicated technical forum focused on optimizing process development for plasmid and cell-free DNA\, adhering to regulatory requirements to streamline IND approvals for advanced therapies\, and developing scalable\, efficient manufacturing solutions.\nIndustry experts from the likes of Pfizer\, Sanofi\, Novartis\, Beam Therapeutics\, Moderna\, Merck and Chroma Medicine are uniting to share innovations in plasmid design\, advances off-the-shelf lysis equipment and purification techniques\, and strategies to support timely\, cost-efficient large-scale DNA production. \nFind out more: https://ter.li/7k68s7
URL:http://www.pharmajournalist.com/event/2nd-dna-process-development-manufacturing-summit/
LOCATION:The Hyatt Regency\, 1 Ave de Lafayette\, Boston\, MA\, 02111\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250325
DTEND;VALUE=DATE:20250328
DTSTAMP:20260515T035249
CREATED:20250123T121746Z
LAST-MODIFIED:20250123T121746Z
UID:40347-1742860800-1743119999@www.pharmajournalist.com
SUMMARY:7th Treg-Directed Therapies Summit
DESCRIPTION:Over the past year\, the Treg sector has seen groundbreaking investments and strategic collaborations between leading biotech and pharma companies like Quell and AstraZeneca\, and Parvus and AbbVie\, creating a surge of innovation and spotlighting Treg cell therapies and modulators as the next frontier in autoimmune and inflammatory disease treatments. Tregs hold the potential to revolutionize care for conditions that have long lacked effective solutions and are the future of precision medicine in autoimmune and inflammatory diseases. \n \nThe 7th Treg-Directed Therapies Summit is your premier event dedicated to exploring and overcoming the unique challenges and advancements specific to Treg. Offering you exclusive access to the latest industry insights\, clinical data\, Treg biology breakthroughs and strategies for advancing therapies to the clinic from trailblazing companies and academic leaders\, including Abata Therapeutics\, Harvard Medical School\, Nektar Therapeutics\, Parvus Therapeutics\, PolTreg\, ThyTech and many more! \nWhether you are in discovery\, navigating the complexities of IND filings\, or transitioning to the clinic\, this forum provides an unparalleled opportunity to engage with leaders at the forefront of cell therapy and modulator innovation. Connect with senior experts in cell therapy manufacturing and modulator production\, build strategic relationships with investors\, pharmaceutical companies and academics\, opening doors to future collaborations and partnership opportunities. \nEvent guide link: https://ter.li/adqtg1
URL:http://www.pharmajournalist.com/event/7th-treg-directed-therapies-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250325
DTEND;VALUE=DATE:20250328
DTSTAMP:20260515T035249
CREATED:20250116T124349Z
LAST-MODIFIED:20250116T124349Z
UID:40335-1742860800-1743119999@www.pharmajournalist.com
SUMMARY:2nd EHS for Biopharma Summit East
DESCRIPTION:As the biopharma industry evolves with rapid advancements in drug development\, manufacturing\, and research\, EHS leaders are tasked with safeguarding employee health\, maintaining a culture of safety\, and addressing environmental concerns. Navigating these challenges while meeting sustainability goals and mitigating risks has become essential for operational success. EHS professionals must continuously adapt to this dynamic landscape to protect their most valuable asset: their workforce. \nThe 2nd EHS for Biopharma East Summit is an essential event for EHS professionals working in the biopharma industry\, focused on overcoming the sector’s unique regulatory and operational challenges. With over 100+ attendees\, this summit will provide valuable insights on navigating evolving regulations\, optimizing safety protocols\, and enhancing environmental stewardship. Whether your goal is to strengthen safety culture\, reduce incidents\, or achieve sustainability targets\, the summit offers the tools\, knowledge\, and networking opportunities necessary to elevate EHS practices. \nWhat can you expect? – Your Definitive Guide to EHS for Biopharma \n\nDiscover actionable strategies for managing global EHS challenges with insights from Astellas\, MilliporeSigma\, and Elanco\nEnhance safety culture in laboratory and manufacturing settings with guidance from AstraZeneca\, Texcell\, and Cytovance\nLearn best practices for embedding EHS programs within the workforce\, fostering leadership buy-in\, employee engagement\, and promoting psychological well-being to minimize burnout\nExplore the latest technologies driving EHS excellence with expertise from AstraZeneca and Sanofi\nConnect with industry peers to network and benchmark best practices.\nEarn continuing education credits from BCSP\, ABSA\, and CIH\n\nCreated for EHS professionals spanning EHS directors\, EHS managers and EHS technical experts focused on workplace safety\, environmental compliance\, and operational excellence. \nJoin us this March \nFind out more here \nRegister your place
URL:http://www.pharmajournalist.com/event/2nd-ehs-for-biopharma-summit-east/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250325
DTEND;VALUE=DATE:20250328
DTSTAMP:20260515T035249
CREATED:20241212T121823Z
LAST-MODIFIED:20241212T121823Z
UID:40241-1742860800-1743119999@www.pharmajournalist.com
SUMMARY:2nd Biophysics for Drug Discovery Summit
DESCRIPTION:In today’s complex drug development landscape\, leveraging biophysical tools to unravel the molecular and target engagement intricacies of drug candidates is more critical than ever for successfully advancing molecules through the drug development pipeline. The 2nd Biophysics for Drug Discovery Summit is your exclusive opportunity to unite and network with your biophysics and drug discovery peers and delve into the application of biophysical techniques including SPR\, NMR\, Thermal shift assays\, mass spec\, and the emerging technologies\, across modalities and targets to inform efficient drug discovery. \n \nThe Biophysics for Drug Discovery Summit will delve into the latest in strategy and application of biophysical techniques across novel targets and modalities\, from AI-driven drug discovery to fragment-based drug discovery\, and in-cell biophysics to single-particle tracking. By understanding the intricate molecular mechanisms and improving hit selection and target identification\, we can accelerate the discovery of innovative therapies and improve the effectiveness and efficiency of drug development. \nUnlock the future of therapeutics through biophysics and keep up to date as field evolves into new technologies and applications\, this meeting will provide you with thought-provoking insights on biophysics applications to take away to your wider drug discovery teams. Join the Biophysics for Drug Discovery Summit in March 2025 and build meaningful connections with 70+ biophysicists and drug discovery experts and move the field forward with unique insights and deep-dive conversations. \nTo know more visit: https://ter.li/8u0s3n
URL:http://www.pharmajournalist.com/event/2nd-biophysics-for-drug-discovery-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250325
DTEND;VALUE=DATE:20250328
DTSTAMP:20260515T035249
CREATED:20241127T125100Z
LAST-MODIFIED:20241127T125100Z
UID:40163-1742860800-1743119999@www.pharmajournalist.com
SUMMARY:8th Gene Therapy Development Summit
DESCRIPTION:With 14 new gene therapy approvals in the last 18 months\, billion-dollar collaborations\, and the development of treatments for more common conditions\, the gene therapy field is rapidly gaining momentum and broadening scope beyond rare diseases. \nReturning to Boston in March\, the 8th Gene Therapy Development Summit\, formerly known as the Gene Therapy for Rare Disorders Summit\, will unite 200+ gene therapy experts to tackle the field’s biggest challenges of achieving genuine scalability and accessibility to meet growing patient demand. \nFor the first time\, this industry-defining meeting will reflect the field’s growing focus on developing therapies for common diseases\, whilst addressing existing hurdles in rare and ultra-rare disorders. This is your unparalleled opportunity to delve into: \n\nThe latest global regulatory requirements\nOptimizing routes for CNS\nOcular and inner ear disorders\nInnovations in capsid engineering and dosing strategies\nIncreasing volumetric productivity to reduce CoGs\n\nVIEW THE FULL EVENT GUIDE \nSecure your place here or get in touch with the team – info@hansonwade.com
URL:http://www.pharmajournalist.com/event/8th-gene-therapy-development-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:General Enquiries: info@hansonwade.com or Partnership Enquiries: sponsor@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250325
DTEND;VALUE=DATE:20250328
DTSTAMP:20260515T035249
CREATED:20241127T122738Z
LAST-MODIFIED:20241127T122738Z
UID:40140-1742860800-1743119999@www.pharmajournalist.com
SUMMARY:4th Novel Conjugate Summit
DESCRIPTION:The field of conjugatable drugs is advancing at a rapid pace\, with major collaborations like Nurix & Pfizer for antibody-degrader conjugates and Bicycle & Novartis for radiopharmaceuticals\, which paves the way towards a new generation of more targeted\, safer and efficacious novel conjugated drugs. \nThe 4th Novel Conjugates Summit is the only event offering comprehensive insights into the latest innovations in bioconjugates. From antibody-degrader conjugates to bispecific ADCs and peptide drug conjugates\, join us to delve into each of their value propositions and navigate crucial considerations like target selection\, PK/PD profiles\, and translation into the clinic. \nConnect with 100+ experts from big pharma\, cutting-edge biotechs and conjugation and manufacturing providers\, all sharing crucial insights on striking success with new formats and payloads. \nNow is the time to expand your conjugate design toolkit to pursue emerging cancer targets and stay ahead in the race to deliver safer\, more targeted therapies beyond traditional ADCs Join us to explore the most promising new targeting vectors and payloads that are set to revolutionize the landscape of conjugated drugs in 2025!
URL:http://www.pharmajournalist.com/event/4th-novel-conjugate-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250318
DTEND;VALUE=DATE:20250321
DTSTAMP:20260515T035249
CREATED:20250127T202012Z
LAST-MODIFIED:20250127T202012Z
UID:40377-1742256000-1742515199@www.pharmajournalist.com
SUMMARY:5th Wet AMD Diabetic Eye Disease Drug Summit
DESCRIPTION:With Merck’s acquisition of EyeBio for $1.3 Billion\, Roche’s Vabysmo launch success and multiple other phase II and III trials in DME\, DR\, RVO\, and Wet AMD\, there is plenty to discuss in the retinal vascular drug space as drug developers seek to new alternatives to anti-VEGF\, explore biosimilars\, and target retinal fibrosis and more to find truly transformative drugs for patients. \n \nThe 2025 Wet AMD & Diabetic Eye Disease Summit is set to be an essential meeting for industry leaders\, research innovators\, and clinical experts dedicated to transforming the landscape of retinal vascular disease treatments. \nWhat’s New for the 2025 Wet AMD & Diabetic Eye Disease Drug Summit? \n\nNew Strategies for Retinal Vascular Drug Clinical Trials: Delve into advanced strategies for designing clinical trials in Wet AMD and diabetic eye disease\, focusing on patient-specific factors and adaptive trial models with insights from Bayer and Aviceda Therapeutics\nEmerging Biomarker Approaches Wet AMD\, DR. DME & RVO: Explore the critical role of biomarkers and clinical endpoints in developing therapies for neovascular retinal disorders\, featuring discussions from Opus Genetics and Ocugen\nInnovative Oral Anti-Inflammatory Treatments for Diabetic Eye Disease: Discover how InflammX Therapeutics is addressing the unmet need in DR and DME patients non-responsive to anti-VEGF therapy with their once-daily oral small molecule\nAdvancements in Retinal Drug Delivery: Discover the benefits of suprachoroidal TKI delivery for Wet AMD with Clearside Biomedical\, and hear from Sanofi about incorporating drug delivery devices to improve physician efficiency and patient compliance\nBreakthroughs in Wet AMD Gene Therapy: Learn about emerging gene therapies for Wet AMD\, focusing on innovative approaches and potential impact on patient care with HuidaGene Therapeutics Doheny Eye Centers\n\nJoin 50+ biopharma experts from clinical\, medical\, regulatory. value and access departments from Bayer\, Sanofi\, EyePoint\, Ocular Therapeutix\, Clearside Biomedical\, RevOpsis\, Opus Genetics\, and HuidaGene Therapeutics as they accelerate towards releasing longer-lasting\, non-invasive and more effective drugs for retinal disease patients. \nTo know more visit: https://ter.li/sew767
URL:http://www.pharmajournalist.com/event/5th-wet-amd-diabetic-eye-disease-drug-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR